Clinical Trial Update: Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating maraviroc for modulation of atherosclerosis in HIV patients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cardiovascular Disease
• HIV Infection

Drugs mentioned

• Maraviroc (maraviroc)

Snippet

Sponsor: University Of Perugia | Conditions: HIV Infection With Other Conditions, Cardiovascular Risk Factor | Phase 4 | Status: COMPLETED